Publications by authors named "Axelle Benchimol-Zouari"
Article Synopsis
- Cabozantinib, a treatment for metastatic renal cell carcinoma (mRCC), may lead to significant weight and muscle loss, which is under-researched in this context.
- A study analyzed 101 mRCC patients treated with cabozantinib, revealing that 85 experienced muscle loss, especially after 6 months, and many started with or developed sarcopenia (muscle wasting) during treatment.
- The presence of baseline sarcopenia was linked to lower treatment response rates and higher occurrences of severe side effects, with nearly half of the patients analyzed also experiencing significant weight loss.
Background: Cabozantinib, a potent multityrosine kinases inhibitor (TKI), has demonstrated overall survival (OS) benefit over everolimus in patients previously treated with VEGFR TKI for metastatic Renal Cell Carcinoma (mRCC). The efficacy of systemic treatments after cabozantinib failure has not been investigated.
Materials And Methods: We conducted a retrospective study on patients receiving systemic treatment after cabozantinib failure in heavily pretreated patient with mRCC.